Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, received a 3-day suspension order for the drug license of its store at Surya Nagar Colony Mallpur in Telangana. The order was issued by the Assistant Director, Drugs Control Administration, Shameerpet, under Rule 65 of the Drugs and Cosmetics Act, 1940, and was received on February 22, 2026. The company estimates a potential revenue loss of Rs 0.76 lakhs from this suspension, indicating a single-store, short-duration impact. The disclosure has been made to stock exchanges under SEBI Listing Regulations as a routine regulatory update.
The financial impact is negligible — under ₹1 lakh in potential revenue loss from one store over three days — and is unlikely to have any meaningful effect on the company's overall operations or stock price.